07.08.24 -- The Path Forward For CLL Is Allogeneic

Selecting a CDMO isn't just entering a transactional relationship. You're forming a long-term partnership that can impact the success of your current products and benefit future product manufacturing.

Advancements in viral vector design and manufacturing have yielded significant improvements in key areas. This resource helps to keep abreast of innovations in this dynamic and rapidly evolving space.

This study demonstrates the effect of different promoters and PREs (Post-Regulatory Element) on multiple CAR and transgenic TCR constructs on titer, integration, expression, and in vitro function.

Review an innovative approach to fast-tracking AAVs through a platform approach that easily scales as the project progresses to late-stage GMP production and to market.

Build a reliable, de-risked path to the clinic while avoiding unforeseen costs and compliance-related delays with advice from Suparna Sanyal, PhD, Head of Viral Vectors Commercial Development.

For the robust manufacturing of the serotype AAV6, the Pro10™ production platform has proven reliability and scalability, making it suitable for meeting the demands of large-scale manufacturing.